[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645531":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":29,"collaborators":11,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":11,"eligibilityCriteria":38,"healthyVolunteers":35,"sex":39,"minAge":40,"maxAge":11,"enrollmentInfo":41,"targetDuration":11,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":11,"overallStatus":50,"whyStopped":11,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":11},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"The intervention group","EXPERIMENTAL",null,[13],"Drug: Lemborexant Pill",{"label":15,"type":16,"description":11,"interventionNames":17},"The control group","PLACEBO_COMPARATOR",[18],"Drug: Placebo tablet",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Lemborexant Pill","The intervention group will take Lemborexant tablets four times during the perioperative period",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo tablet","The control group will take placebo tablets with the same appearance, smell and properties as the intervention group four times during the perioperative period",[15],{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ruquan Han","Principal Investigator","100645531","phase-2-lemborexant-use-for-cognition-improvement-in-postoperative-delirium-in-elderly-patients-a-randomized-controlled-trial-100645531",false,"NCT07695285","Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥60 years old;\n* ASA classification I to III;\n* Patients undergoing elective surgery;\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* Tracheal intubation is expected to be retained after the operation;\n* Previous history of alcohol or drug abuse;\n* Severe abnormalities in liver and kidney functions;\n* Long-term use of sedative-hypnotic drugs;\n* Severe sleep apnea and COPD;\n* Inability to cooperate in mental state;\n* Craniocerebral surgery\n* Pregnant and lactating patients;\n* Use drugs that affect orexin metabolism.","ALL","60 Years",{"count":42,"type":43},992,"ESTIMATED","INTERVENTIONAL",[46],"PHASE2","This prospective, randomized controlled trial aims to investigate the perioperative use of lemborexant, an orexin receptor antagonist, for reducing postoperative delirium (POD) in elderly patients undergoing general anesthesia.",[49],"Postoperative Delirium","NOT_YET_RECRUITING","2026-07-12",{"date":53,"type":54},"2026-07-14","ACTUAL",{"date":56,"type":43},"2026-09-01",{"date":58,"type":43},"2029-12-31",{"name":5,"class":6}]